Khat Chewing and Clinical Conditions Determine the Epidemiology of Primary Drug Resistance Tuberculosis in Amhara Region of Ethiopia: A Multicenter Study

References

• World Health Organization. Global Tuberculosis Report. Geneva: World Health Organization; 2019.
   Google Scholar
• He XC, Zhang XX, Zhao JN, et al. Epidemiological Trends of Drug-Resistant Tuberculosis in China From 2007 to 2014: a Retrospective Study. Medicine. 2016;95(15):e3336. doi:10.1097/MD.000000000000333627082586
   PubMed Web of Science ®Google Scholar
• Bloom BR, Atun R, Cohen T, et al. Tuberculosis. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. Washington (DC): The International Bank for Reconstruction and Development/The World Bank © 2017 International Bank for Reconstruction and Development/The World Bank; 2017.
   Google Scholar
• Ministry of Health-Ethiopia. National Programmatic Management of Drug-Resistant TB (PMDT) in Ethiopia. Ministry of Health-Ethiopia; 2019.
   Google Scholar
• Tulu B, Ameni G. Spoligotyping based genetic diversity of Mycobacterium tuberculosis in Ethiopia: a systematic review. BMC Infect Dis. 2018;18(1):140. doi:10.1186/s12879-018-3046-429587640
   PubMed Web of Science ®Google Scholar
• Yimer SA, Hailu E, Derese Y, Bjune GA, Holm-Hansen C. Spoligotyping of Mycobacterium tuberculosis isolates among pulmonary tuberculosis patients in Amhara Region, Ethiopia. APMIS. 2013;121(9):878–885. doi:10.1111/apm.1204623336257
   PubMed Web of Science ®Google Scholar
• Schito M, Hanna D, Zumla A. Tuberculosis eradication versus control. Int j Infect Dis. 2017;56:10–13. doi:10.1016/j.ijid.2016.11.00727872016
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHO Consolidated Guidelines on Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization; 2019.
   Google Scholar
• Adhvaryu M, Vakharia B. Drug-resistant tuberculosis: emerging treatment options. Clin Pharmacol. 2011;3:51–67. doi:10.2147/CPAA.S1159722287857
   PubMedGoogle Scholar
• Yashodhara BM, Huat CB, Naik LN, Umakanth S, Hande M, Pappachan JM. Multidrug and extensively drug-resistant tuberculosis from a general practice perspective. Infect Drug Resist. 2010;3:115–122. doi:10.2147/IDR.S1074321694900
   PubMedGoogle Scholar
• Li WB, Zhang YQ, Xing J, Ma ZY, Qu YH, Li XX. Factors associated with primary transmission of multidrug-resistant tuberculosis compared with healthy controls in Henan Province, China. Infect Dis Poverty. 2015;4:14. doi:10.1186/s40249-015-0045-125806104
   PubMed Web of Science ®Google Scholar
• Li XX, Lu W, Zu RQ, et al. Comparing risk factors for primary multidrug-resistant tuberculosis and primary drug-susceptible tuberculosis in Jiangsu province, China: a matched-pairs case-control study. Am J Trop Med Hyg. 2015;92(2):280–285. doi:10.4269/ajtmh.13-071725535310
   PubMed Web of Science ®Google Scholar
• Tefera KT, Mesfin N, Reta MM, Sisay MM, Tamirat KS. Treatment delay and associated factors among adults with drug resistant tuberculosis at treatment initiating centers in the Amhara regional state, Ethiopia. BMC Infect Dis. 2019;19(1):489. doi:10.1186/s12879-019-4112-231151423
   PubMed Web of Science ®Google Scholar
• Alene KA, Yi H, Viney K, et al. Treatment outcomes of patients with multidrug-resistant and extensively drug resistant tuberculosis in Hunan Province, China. BMC Infect Dis. 2017;17(1):573. doi:10.1186/s12879-017-2662-828814276
   PubMed Web of Science ®Google Scholar
• Bastos ML, Cosme LB, Fregona G. Treatment outcomes of MDR-tuberculosis patients in Brazil: a retrospective cohort analysis. BMC Infect Dis. 2017;17(1):718. doi:10.1186/s12879-017-2810-129137626
   PubMed Web of Science ®Google Scholar
• Limenih YA, Workie DL. Survival analysis of time to cure on multi-drug resistance tuberculosis patients in Amhara region, Ethiopia. BMC Public Health. 2019;19(1):165. doi:10.1186/s12889-019-6500-330732601
   PubMed Web of Science ®Google Scholar
• Maharaj J, Ross A, Maharaj NR, Campbell L. Multidrug-resistant tuberculosis in KwaZulu-Natal, South Africa: an overview of patients’ reported knowledge and attitudes. African j Primary Health Care Family Med. 2016;8(1):e1–6. doi:10.4102/phcfm.v8i1.1089
   Google Scholar
• Ershova JV, Volchenkov GV, Kaminski DA, et al. Epidemiology of Primary Multidrug-Resistant Tuberculosis, Vladimir Region, Russia. Antimicrob Resist Infect Control. 2015;21(11):2048–2051.
   Google Scholar
• Royce S, Falzon D, van Weezenbeek C, et al. Multidrug resistance in new tuberculosis patients: burden and implications. Int j Tuberculosis Lung Dis. 2013;17(4):511–513. doi:10.5588/ijtld.12.0286
   Web of Science ®Google Scholar
• Shibabaw A, Gelaw B, Wang SH, Tessema B. Time to sputum smear and culture conversions in multidrug resistant tuberculosis at University of Gondar Hospital, Northwest Ethiopia. PLoS One. 2018;13(6):e0198080. doi:10.1371/journal.pone.019808029944658
   PubMed Web of Science ®Google Scholar
• Yihunie Akalu T, Muchie KF, Alemu Gelaye K. Time to sputum culture conversion and its determinants among Multi-drug resistant Tuberculosis patients at public hospitals of the Amhara Regional State: a multicenter retrospective follow up study. PLoS Med. 2018;13(6):e0199320. doi:10.1371/journal.pone.0199320
   Web of Science ®Google Scholar
• Kendall EA, Azman AS, Cobelens FG, Dowdy DW. MDR-TB treatment as prevention: the projected population-level impact of expanded treatment for multidrug-resistant tuberculosis. PLoS One. 2017;12(3):e0172748. doi:10.1371/journal.pone.017274828273116
   PubMed Web of Science ®Google Scholar
• Azman AS, Cobelens FG, Dowdy DW, Song WM. Primary drug resistance of mycobacterium tuberculosis in Shandong, China, 2004–2018. PLoS One. 2019;20(1):223.
   Google Scholar
• Mesfin YM, Hailemariam D, Biadgilign S, Kibret KT. Association between HIV/AIDS and multi-drug resistance tuberculosis: a systematic review and meta-analysis. PLoS One. 2014;9(1):e82235. doi:10.1371/journal.pone.008223524416139
   PubMed Web of Science ®Google Scholar
• Conaty SJ, Hayward AC, Story A, Glynn JR, Drobniewski FA, Watson JM. Explaining risk factors for drug-resistant tuberculosis in England and Wales: contribution of primary and secondary drug resistance. Epidemiol Infect. 2004;132(6):1099–1108. doi:10.1017/S095026880400286915635967
   PubMed Web of Science ®Google Scholar
• Sharma M, Roy N, Banerjee R, Kishore J, Jakhar A. Determinants of Drug Resistance in Previously-Treated Pulmonary Tuberculosis Patients Registered at a Chest Clinic in South Delhi, India. Cureus. 2019;11(8):e5541.31523588
   PubMed Web of Science ®Google Scholar
• Desissa F, Workineh T, Beyene T. Risk factors for the occurrence of multidrug-resistant tuberculosis among patients undergoing multidrug-resistant tuberculosis treatment in East Shoa, Ethiopia. PLoS One. 2018;18(1):422.
   Google Scholar
• Silva DR, Muñoz-Torrico M, Duarte R, et al. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. J Brasileiro De Pneumologia. 2018;44(2):145–152. doi:10.1590/s1806-37562017000000443
   Web of Science ®Google Scholar
• Likhtanskiĭ GP. Experience with the compulsory treatment of patients with pulmonary tuberculosis and alcoholism. Likars’ka Sprava. 1992;1(2):105–107.
   Google Scholar